Pure Global
NCT06416345

Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson's Disease

Amsterdam UMC, location VUmc·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Parkinson Disease
Drug/Device/Intervention
Cue2Walk
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Amsterdam UMC, location VUmc
Location
Amsterdam, Netherlands
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2024
End date
Sep 01, 2027
Enrollment
84 participants
Primary outcome

Self-reported quality of life,General health-related quality of life,Time in Freezing of Gait

Summary

The majority of people with Parkinson's disease incur Freezing of Gait (FoG), which is not
 addressed adequately by medication. Cueing is a proven strategy to overcome FoG. The Cue2Walk
 is a device with automated detection of FoG and provision of rhythmic cues. In this study,
 the (cost-)effectiveness of the Cue2Walk device as compared to usual care is investigated.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismSecondary parkinsonism, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06416345
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06416345 through Pure Global AI's free database. This phase not specified trial is sponsored by Amsterdam UMC, location VUmc and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 84 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.